In the past week, VVOS stock has gone down by -8.11%, with a monthly decline of -20.93% and a quarterly plunge of -58.61%. The volatility ratio for the week is 7.20%, and the volatility levels for the last 30 days are 9.66% for Vivos Therapeutics Inc The simple moving average for the past 20 days is -10.49% for VVOS’s stock, with a -63.91% simple moving average for the past 200 days.
Is It Worth Investing in Vivos Therapeutics Inc (NASDAQ: VVOS) Right Now?
Company’s 36-month beta value is 7.98.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VVOS is 2.76M, and currently, short sellers hold a 6.92% ratio of that floaft. The average trading volume of VVOS on May 07, 2024 was 185.21K shares.
VVOS) stock’s latest price update
Vivos Therapeutics Inc (NASDAQ: VVOS)’s stock price has gone decline by -9.51 in comparison to its previous close of 2.63, however, the company has experienced a -8.11% decrease in its stock price over the last five trading days. Proactive Investors reported 2024-04-11 that Vivos Therapeutics (NASDAQ:VVOS) CEO Kirk Huntsman expects to see more medical and dental professionals recommending its oral medical devices for obstructive sleep apnea (OSA) after they secured Medicare reimbursement approval. The company announced earlier this week that its CARE oral medical devices, an alternative to continuous positive airway pressure (CPAP) for patients with OSA, have been approved for Medicare reimbursement by the Centers for Medicare and Medicaid Services (CMS).
VVOS Trading at -37.48% from the 50-Day Moving Average
After a stumble in the market that brought VVOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.12% of loss for the given period.
Volatility was left at 9.66%, however, over the last 30 days, the volatility rate increased by 7.20%, as shares sank -21.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.43% lower at present.
During the last 5 trading sessions, VVOS fell by -8.11%, which changed the moving average for the period of 200-days by -66.50% in comparison to the 20-day moving average, which settled at $2.63. In addition, Vivos Therapeutics Inc saw -80.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VVOS starting from Huntsman Ronald Kirk, who purchase 14,000 shares at the price of $0.53 back on Jun 20 ’23. After this action, Huntsman Ronald Kirk now owns 86,521 shares of Vivos Therapeutics Inc, valued at $7,420 using the latest closing price.
Huntsman Ronald Kirk, the Chief Executive Officer of Vivos Therapeutics Inc, purchase 15,000 shares at $0.54 during a trade that took place back on Jun 16 ’23, which means that Huntsman Ronald Kirk is holding 72,521 shares at $8,050 based on the most recent closing price.
Stock Fundamentals for VVOS
Current profitability levels for the company are sitting at:
- -1.25 for the present operating margin
- 0.59 for the gross margin
The net margin for Vivos Therapeutics Inc stands at -0.51. The total capital return value is set at -5.03. Equity return is now at value -521.22, with -111.11 for asset returns.
Based on Vivos Therapeutics Inc (VVOS), the company’s capital structure generated 0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -5.99. The debt to equity ratio resting at 4.85. The interest coverage ratio of the stock is 5.24.
Currently, EBITDA for the company is -16.68 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 0.54. The receivables turnover for the company is 68.32for trailing twelve months and the total asset turnover is 1.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.34.
Conclusion
In a nutshell, Vivos Therapeutics Inc (VVOS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
